This research group also investigated the immune response in HD patients, 90% without previous infection, and observed a booster effect on anti-RBD and neutralizing antibodies to different variants and a significant increase in SARS-CoV-2-S-IFN-γ-producing T-cells 46 days after receiving the third homologous mRNA vaccine dose [12]. The gene discussed is IFNG; the disease is infection.